113240-61-2

Basic information

• Product Name: Hexanoic acid, 5-hydroxy-3-oxo-6-(triphenylmethoxy)-, 1,1-dimethylethyl ester, (S)-
• CAS NO: 113240-61-2
• Molecular Formula: C29H32O5
• Molecular Weight: 460.57
• Mol File: 113240-61-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Hexanoic acid, 5-hydroxy-3-oxo-6-(triphenylmethoxy)-, 1,1-dimethylethyl ester, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Hexanoic acid, 5-hydroxy-3-oxo-6-(triphenylmethoxy)-, 1,1-dimethylethyl ester, (S)-(113240-61-2)
• EPA Substance Registry System: Hexanoic acid, 5-hydroxy-3-oxo-6-(triphenylmethoxy)-, 1,1-dimethylethyl ester, (S)-(113240-61-2)

Safety Data

• Hazardous Substances Data: 113240-61-2(Hazardous Substances Data)

Usage

General Description

Hexanoic acid, 5-hydroxy-3-oxo-6-(triphenylmethoxy)-, 1,1-dimethylethyl ester, (S)- is a chemical compound commonly referred to as an ester. It is derived from hexanoic acid and has a 5-hydroxy-3-oxo-6-(triphenylmethoxy) structure. The compound is specifically in its (S)- form, indicating its stereochemistry. It exists in the form of a clear, colorless to pale yellow liquid, and it is used in various industrial applications such as in the production of perfumes, flavorings, and as a solvent in chemical reactions. Additionally, it can also be used as a precursor in the synthesis of other organic compounds.

Upstream product

• 144754-24-5 (S)-methyl 3-hydroxy-4-(trityloxy)butanoate 
• 540-88-5 acetic acid tert-butyl ester 
• 150942-98-6 t-butyl lithioacetate 
• 109-72-8 n-butyllithium 
• 131666-63-2 (S)-3-hydroxy-4-triphenylmethoxybutanenitrile 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 7440-66-6 zinc 
• 144754-24-5 methyl (R)-3-hydroxy-4-(triphenylmethyl)oxybutanoate 

Downstream Products

• 123477-30-5 1,1-Dimethylethyl (3R,5S)-3,5-di-[(1',1'-dimethylethyl)-diphenylsilyloxy]-6-oxohexanoate 
• 130852-63-0 (3S,5S)-3,5-Bis-(tert-butyl-diphenyl-silanyloxy)-6-oxo-hexanoic acid tert-butyl ester 
• 123492-49-9 1,1-Dimethylethyl (3R,5S)-3,5-di[(1-,1-dimethylethyl)diphenylsilyloxy]-6-hydroxyhexanoate 
• 129893-64-7 (3S,5S)-3,5-Bis-(tert-butyl-diphenyl-silanyloxy)-6-hydroxy-hexanoic acid tert-butyl ester 
• 123477-29-2 1,1-Dimethylethyl (3R,5S)-3,5-di-[(1',1'-dimethylethyl)-diphenylsilyloxy]-6-(triphenylmethoxy)hexanoate 
• 130852-62-9 (3S,5S)-3,5-Bis-(tert-butyl-diphenyl-silanyloxy)-6-trityloxy-hexanoic acid tert-butyl ester 
• 130852-64-1 (3R,5R)-3,5-Bis-(tert-butyl-diphenyl-silanyloxy)-6-oxo-hexanoic acid tert-butyl ester 
• 116168-28-6 (3S,5R)-3,5-Bis-(tert-butyl-diphenyl-silanyloxy)-6-oxo-hexanoic acid tert-butyl ester 
• 123492-49-9 (3R,5R)-3,5-Bis-(tert-butyl-diphenyl-silanyloxy)-6-hydroxy-hexanoic acid tert-butyl ester 
• 123492-49-9 (3S,5R)-3,5-Bis-(tert-butyl-diphenyl-silanyloxy)-6-hydroxy-hexanoic acid tert-butyl ester 
• 123477-29-2 (3R,5R)-3,5-Bis-(tert-butyl-diphenyl-silanyloxy)-6-trityloxy-hexanoic acid tert-butyl ester 
• 123477-29-2 (3S,5R)-3,5-Bis-(tert-butyl-diphenyl-silanyloxy)-6-trityloxy-hexanoic acid tert-butyl ester 
• 123477-28-1 1,1-Dimethylethyl (3R,5S)-3,5-dihydroxy-6-(triphenylmethoxy)hexanoate 
• 130852-61-8 (3S,5S)-3,5-Dihydroxy-6-trityloxy-hexanoic acid tert-butyl ester 

Relevant articles and documents

Novel boronate esters

The present invention relates to optically active boronate derivatives which are useful as intermediates for the synthesis of HMG-CoA enzyme inhibitors such as atorvastatin, cerivastatin, rosuvastatin, pitavastatin, and fluvastatin.

A Highly Stereoselective Route to the Four Stereoisomers of a Six-Carbon Synthon

The syntheses of chiral synthones 13-16 are described utilizing the chiral pool approach starting from either S- or R-malic acid.

Imidazole analogs of mevalonolactone and derivatives thereof for use in inhibiting cholesterol biosynthesis and lowering blood cholesterol level

Compounds of the formula STR1 and the pharmaceutically acceptable acid addition salts thereof, wherein the various substituents are defined hereinbelow and the use thereof for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, in the treatment of hyperlipoproteinemia and atherosclerosis, pharmaceutical compositions comprising such compounds and processes for and intermediates in the synthesis of such compounds.